Pazopanib is a kinase inhibitor indicated for the treatment of adults with advanced renal cell carcinoma (RCC), among other approved uses. It is available as tablets for oral use. MedsAcross supplies Pazopanib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.
Source: US FDA prescribing information
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.
Source: US FDA prescribing information
Recommended Dosage: 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Moderate Hepatic Impairment: 200 mg orally once daily.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Boxed warning (hepatotoxicity): Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred. Monitor liver tests at baseline, regularly during treatment and as clinically indicated. Withhold VOTRIENT and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity. QT Prolongation and Torsades de Pointes: Monitor patients who are at significant risk of developing QT interval prolongation. Monitor electrocardiograms (ECGs) and electrolytes at baseline and as clinically indicated. Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiating VOTRIENT and during treatment.
Source: US FDA prescribing information
The following clinically significant adverse reactions are elsewhere in the labeling: Hepatic Toxicity QT Prolongation and Torsades de Pointes Cardiac Dysfunction Hemorrhagic Events Arterial Thromboembolic Events Venous Thromboembolic Events Thrombotic Microangiopathy (TMA) Gastrointestinal Perforation and Fistula Interstitial Lung Disease (ILD)/Pneumonitis Posterior Reversible Encephalopathy Syndrome (PRES) Hypertension Hypothyroidism Proteinuria Tumor Lysis Syndrome Infection The most common adverse reactions in patients with RCC (≥ 20%) are diarrhea, hypertension, hair color changes (depigmentation), nausea, anorexia, and vomiting.
Source: US FDA prescribing information
Strong CYP3A4 Inhibitors: Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dose of VOTRIENT. Strong CYP3A4 Inducers: Consider an alternate concomitant medication with no or minimal enzyme induction potential. VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. CYP Substrates: Coadministration of VOTRIENT with agents with narrow therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 is not recommended. Concomitant Use With Simvastatin: Concomitant use of VOTRIENT with simvastatin increases the risk of alanine aminotransferase (ALT) elevations. Increase to weekly monitoring of liver function as recommended. Withhold VOTRIENT and resume at reduced dose, or permanently discontinue based on severity of hepatotoxicity.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Pazopanib, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Pazopanib 200 mg tabletOralGeneric name | — | US FDA | Available on request |
| Pazopanib 400 mg tabletOralGeneric name | — | US FDA | Available on request |
| Votrient 200 mg tabletOral | Novartis Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Pazopanib in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Pazopanib and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Pazopanib, including Votrient.
Yes. The US FDA first approved Pazopanib on 19 October 2009, according to Drugs@FDA.
Yes. Pazopanib has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Pazopanib is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Pazopanib is classified under ATC code L01XE11 (Pazopanib).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.